Cholinergic — attention, encoding & recall
One of 6 mechanistic pathways to 🧠 Focus, memory & cognition · 19 options
Acetylcholine is the neurotransmitter of attention and memory formation. Most racetams increase acetylcholine turnover without supplying more, which is exactly why people get headaches on them and why a choline source is not optional in this pathway.
Check these before buying a nootropic. B12 deficiency produces exactly the symptom picture racetams are sold for, serum B12 misses it, and MMA is the test that doesn't.
Vitamin B12Methylmalonic Acid (MMA)Folate, SerumHomocysteineTSH (Thyroid-Stimulating Hormone)🧠 Brain Fog & Cognition covers these in one panel →
What engages this pathway
Ordered by how directly each one acts on the mechanism above — never by how much trial evidence exists. Each links to its full breakdown with dosing, half-life and vendor.
🧬 Alpha-GPC
The most bioavailable choline donor that crosses the blood-brain barrier. Human trials show improved power output as well as cognition — it raises growth hormone acutely too.
💉 CDP-Choline
Delivers choline plus cytidine, which converts to uridine and supports phospholipid membrane synthesis. Two mechanisms: neurotransmitter substrate and structural repair.
💉 Piracetam
The 1964 parent every other racetam here is a derivative of, and the one with no identified receptor after sixty years — the mechanism on offer is a physico-chemical interaction with phospholipid head groups that alters membrane fluidity, reported as larger in aged brain membranes than young. Its clearest controlled human result is in cortical myoclonus at 2.4-16.8g daily, not in cognition; the Cochrane review for dementia and cognitive impairment does not support that use and has not been updated since 2001. Note the dose gap before judging it: the 800mg and 1200mg tablets sold are a fraction of the only range with a controlled result behind it.
💉 Aniracetam
Fat-soluble racetam with AMPA-receptor modulation and an anxiolytic character the others lack. The European clinical literature is old and mostly in cognitive decline, not healthy users.
💉 Oxiracetam
The most stimulating of the classic racetams, with the clearest reported effect on logical and spatial processing.
💉 Pramiracetam
Markedly increases high-affinity choline uptake — the most choline-hungry racetam, and the one most likely to give you a headache without a donor alongside it.
💉 Phenylpiracetam
A phenyl group added to piracetam adds genuine stimulant and cold-tolerance properties. Tolerance builds fast, which is why cycling is the standard advice.
💉 Nefiracetam
Acts on both cholinergic and NMDA systems, with animal data suggesting mood effects too. Rodent testicular toxicity at high doses is why it never reached market.
💉 Noopept
Not structurally a racetam but functionally similar at roughly a thousandth the dose. It elevates NGF and BDNF in rodents, which is a neurotrophic argument rather than a purely cholinergic one.
🧬 Huperzine A
Acetylcholinesterase inhibition — stops the breakdown rather than supplying substrate. Long half-life means it accumulates, so cycling matters more than people assume.
🧬 Citicoline
The supplement form of CDP-choline, with good human trial support for attention and memory in both older adults and healthy young people.
🧬 Choline Bitartrate
The cheapest choline salt and the worst at crossing into the brain. Fine for liver methylation, poor for cognition.
🧬 Phosphatidylcholine
Structural phospholipid for membrane repair as well as a choline source.
🧬 Uridine Monophosphate
Combined with DHA and choline it increases synapse formation in animal models — the Wurtman synaptogenesis stack. Human data is best in cognitive decline.
🧬 Memory Support
A formulated blend across the cholinergic and circulatory arguments — reasonable as a starting point, less precise than choosing a mechanism.
🧬 Brain Support
Broad cognitive formulation. Judge it on whether its components hit a pathway you actually need.
💉 NeuroDrive Blend
An injectable nootropic blend combining several of the peptides on this page. Convenience at the cost of knowing which component is doing the work.
💉 Donepezil
A prescription acetylcholinesterase inhibitor for Alzheimer's dementia, here because it is the reference point every cholinergic nootropic is implicitly compared against. Its own FDA label states there is no evidence it alters the course of the underlying disease. In an 80-trial individual-patient network meta-analysis it improved MMSE by 1.41 points against the reviewers' own 1.40-point threshold for clinical importance — real, replicated and very small. No buy button: prescription medicine, and it carries bradycardia and heart-block warnings.
💉 Galantamine
The other prescription cholinesterase inhibitor, and the one with a paragraph in its own label that nootropics readers should see: in two 2-year randomized trials in MILD COGNITIVE IMPAIRMENT, 13 patients on galantamine and 1 on placebo died, about half from vascular causes, and it has never been explained. Mild cognitive impairment is the closest studied population to someone whose memory feels a step slower. It also exaggerates neuromuscular blockade under anesthesia. No buy button.
What actually decides this outcome, in order of size
Acetylcholine is made from choline and acetyl-CoA, released, and hydrolyzed within milliseconds. Almost every product here acts on one of those three steps, and which step decides what the compound can and cannot do. Ranked by how much of the outcome each factor owns:
- Sleep, which consolidates what was encoded and is not on the shelf. Encoding without consolidation produces the specific experience of having studied and retained nothing, and no cholinergic agent substitutes for the process. This is the largest lever on the page and it is at Sleep depth, slow-wave & recovery quality.
- Whether there is a cholinergic deficit to correct at all. The human evidence for cholinergic precursors is strongest where the system is degenerating: alpha-GPC in Alzheimer's dementia De Jesus Moreno Moreno 2003 and in amnestic mild cognitive impairment Jeon 2024, and citicoline reviewed across its clinical uses Secades 2006 Grieb 2014. A European regulatory opinion on citicoline and memory support is the counterweight to read beside those EFSA NDA Panel 2024. In a healthy adult with intact synthesis, adding substrate to an unsaturated enzyme is a much weaker proposition than the same molecule tested in disease.
- TURNOVER VERSUS SUPPLY, which is the distinction the whole page turns on. Racetams increase acetylcholine utilization without supplying more choline, which is the mechanistic reason a choline source is described as obligatory alongside them. Aniracetam's own primary action is allosteric potentiation of a glutamate receptor Ito 1990 and it is largely converted to N-anisoyl-GABA in humans Cai 2012 — so the compound reaching the brain is not the compound on the label.
- WHAT THE CHOLINE ITSELF COSTS, which is the sign flip on this page and is measurable. A randomized clinical trial reported that dietary choline supplements, but not eggs, raise fasting TMAO in participants with normal renal function Wilcox 2021. Alpha-GPC specifically has been reported to promote atherosclerosis in a preclinical model Wang 2021, and the enzymatic route from glycerophosphocholine to trimethylamine has been characterized Chen 2024. The intervention that fixes the headache is not metabolically free, and TMAO (Trimethylamine N-oxide) is where that shows.
- Which choline form, because they do not behave alike. Oral CDP-choline raises plasma choline and uridine Wurtman 2000, which is a different profile from a glycerophosphocholine load, and the atherogenic signal above attaches to the latter Wang 2021.
- Whether the racetam has any effect to speak of in a healthy brain. The Cochrane review of piracetam in dementia and cognitive impairment is the reference point Flicker 2001, and the pramiracetam work was done as symptomatic treatment in Alzheimer's disease Claus 1991. Neither population is the reader.
The order to run these in, and what has to be true first
Fix the substrate question and the deficit question before buying anything that raises demand, and know what the substrate costs before making it permanent.
- Baseline bloods, because two correctable deficits present exactly as this complaint. Vitamin B12 with Homocysteine, TSH (Thyroid-Stimulating Hormone) and Ferritin. Cheap, and each has a treatment that is not on this page.
- TMAO (Trimethylamine N-oxide) at baseline if any daily choline product is going to be run for months. This is the number the choline literature actually moved Wilcox 2021, and drawing it first is the only way the later one means anything. Almost nobody on this pathway measures it, which is the specific gap this page exists to close.
- Citicoline or CDP-Choline as the first precursor. Human pharmacokinetics are characterized Wurtman 2000, the clinical review literature is large Secades 2006 Grieb 2014, and a regulatory opinion exists on the memory claim specifically EFSA NDA Panel 2024 — which is worth reading precisely because it is not promotional.
- Alpha-GPC is the better-absorbed precursor and the one with the vascular question attached. It has clinical data in cognitive impairment De Jesus Moreno Moreno 2003 Jeon 2024 and acute performance data in healthy adults Marcus 2017. It is also the form with a preclinical atherosclerosis report Wang 2021 and a described route to trimethylamine Chen 2024. Both halves are true at once.
- Choline Bitartrate is the cheapest and least brain-directed form, and is the one most likely to be doing its trimethylamine chemistry in the gut for very little central benefit.
- Piracetam is the reference racetam and the honest place to start. The Cochrane assessment is the document Flicker 2001. Aniracetam is a different mechanism wearing the same suffix Ito 1990 Cai 2012. Oxiracetam, Pramiracetam Claus 1991, Phenylpiracetam and Nefiracetam are escalations by potency rather than by evidence.
- Noopept is a dipeptide with its own hippocampal electrophysiology Kondratenko 2022, not a racetam, and it is grouped here by marketing rather than by pharmacology.
- Huperzine A is the only item here that is a cholinesterase-inhibiting drug mechanism, which means it raises synaptic acetylcholine by blocking its breakdown rather than by supplying more. That is the mechanism of prescription dementia drugs and it deserves to be treated as one, not as a botanical. Uridine Monophosphate and Phosphatidylcholine are membrane-substrate arguments Wurtman 2000, and Memory Support, Brain Support and NeuroDrive Blend are fixed blends whose doses somebody else chose.
What gets bought for this that cannot move it
The category that fails structurally is the racetam bought without the deficit it was studied in. The clinical literature for these compounds sits in dementia, cognitive impairment and post-stroke recovery Flicker 2001 Claus 1991 Secades 2006, populations in whom the cholinergic system is damaged. In a healthy adult the same molecule is being asked to improve a system that is not limiting, and the effect people report is often the attention cost of the headache going away rather than a gain. A regulatory opinion that declined to accept a memory claim is a useful corrective to read alongside the enthusiastic reviews EFSA NDA Panel 2024.
The direction failure is the fix for the side effect. The page's own internal logic is correct: raise turnover, supply choline. What the logic does not say is that supplying choline has a measured consequence at the other end of the body. A randomized trial reported raised fasting TMAO on choline supplements in people with normal renal function Wilcox 2021; alpha-GPC promoted atherosclerosis in a model Wang 2021; and the enzymology of the conversion has been described Chen 2024. Whether daily long-term precursor dosing in a healthy adult produces a clinically meaningful cardiovascular difference is a prediction from that chain rather than a demonstrated outcome, and it is labeled as one. It is also cheap to check, and nobody does.
The item most likely to be misfiled is the compound that is not what its name implies. Aniracetam acts on a glutamate receptor and is largely present in humans as a metabolite Ito 1990 Cai 2012; Huperzine A is an enzyme inhibitor with a drug mechanism; Noopept is a dipeptide Kondratenko 2022. Three different pharmacologies on one shelf, sold as a graded series.
If the goal underneath is different, so is the page. If the problem is drive and initiation rather than encoding, Catecholamine & dopaminergic drive. If it is the capacity to form connections at all, Glutamatergic & synaptic plasticity. If it is perfusion or fuel, Cerebral metabolism & blood flow. If memory has changed noticeably over months rather than fluctuating with sleep and stress, that is a clinical assessment and not a supplement decision.
How you would know it was working, on a real read-out and a real timescale
This page makes two predictions. TMAO (Trimethylamine N-oxide) will rise on a sustained choline precursor and will not on the racetam beside it, which makes it the one number that separates the two halves of the stack Wilcox 2021; and no product here will change a cognitive score that was measured properly at baseline, in a healthy adult, at eight weeks.
- TMAO (Trimethylamine N-oxide) at baseline and 12 weeks on any daily choline product. Twelve weeks because the reported effect is on fasting levels under sustained intake rather than after a single dose Wilcox 2021, and because a single reading has meal and microbiome noise in it.
- ApoB (Apolipoprotein B) with a Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) at baseline and six months if the precursor is going to be permanent. The vascular question attached to this shelf is preclinical Wang 2021, so this is falsification rather than expectation — and it is the measurement that would make the concern real or dismiss it.
- Vitamin B12 with Homocysteine at baseline. The two reversible causes of exactly this complaint, and homocysteine also reflects the methyl traffic that a choline load feeds into.
- Comprehensive Metabolic Panel (CMP) at baseline and 12 weeks on any racetam. These are daily long-term compounds with limited healthy-adult safety data, and transaminases are the cheapest place a problem would appear.
- A fixed cognitive task, self-administered, same time of day, at baseline and 8 weeks. A digit-span or a timed n-back. Free, repeatable, and more informative than any recollection of how a week felt.
What will fool you. A headache that disappears when choline is added is evidence about the headache, not about cognition. Acute performance findings for Alpha-GPC are single-dose measures in specific tasks Marcus 2017 and do not extrapolate to eight weeks of studying. Caffeine taken alongside anything here will dominate the subjective read-out completely. The strongest clinical results on this shelf come from impaired populations De Jesus Moreno Moreno 2003 Jeon 2024 Secades 2006 and are routinely quoted as though they were healthy-adult data. And a fixed blend hides which of five ingredients did anything, which is why the single agents come first.
Sources read for these sections
- Wilcox J. Dietary Choline Supplements, but Not Eggs, Raise Fasting TMAO Levels in Participants with Normal Renal Function: A Randomized Clinical Trial. American Journal of Medicine 2021 · PMID 33872583
- Wang Z, et al. The Nutritional Supplement L-Alpha Glycerylphosphorylcholine Promotes Atherosclerosis. International Journal of Molecular Sciences 2021 · PMID 34948275
- Chen S. Role of Gpcpd1 in intestinal alpha-glycerophosphocholine metabolism and trimethylamine N-oxide production. J Biol Chem 2024 · PMID 39510189
- Flicker L, Grimley Evans G. Piracetam for dementia or cognitive impairment. Cochrane Database of Systematic Reviews 2001;(2):CD001011 · PMID 11405971
- Jeon J, et al. Efficacy and safety of choline alphoscerate for amnestic mild cognitive impairment: a randomized double-blind placebo-controlled trial. BMC Geriatrics 2024 · PMID 39300341
- De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clinical Therapeutics 2003 · PMID 12637119
- Wurtman RJ. Effect of oral CDP-choline on plasma choline and uridine levels in humans.. Biochem Pharmacol 2000 · PMID 10974208
- EFSA NDA Panel. 'Citicoline' and support of the memory function: Evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal 2024 · PMID 38966137
- Grieb P. Neuroprotective properties of citicoline: facts, doubts and unresolved issues. CNS Drugs 2014 · PMID 24504829
- Marcus L, et al. Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance.. Journal of the International Society of Sports Nutrition 2017 · PMID 29042830
- Claus JJ, Ludwig C, Mohr E, Giuffra M, Blin J, Chase TN. Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam. Neurology 1991;41(4):570-574 · PMID 2011259
- Cai S, Wang L. Determination of aniracetam's main metabolite, N-anisoyl-GABA, in human plasma by LC-MS/MS and its application to a pharmacokinetic study. Journal of Chromatography B 2012;897:50-54 · PMID 22552003
- Kondratenko RV, Povarov IS, Kolbaev SN, Derevyagin VI, Ostrovskaya RU, Gudasheva TA, Sharonova IN, Skrebitsky VG. Effect of nootropic dipeptide noopept on CA1 pyramidal neurons involves α7AChRs on interneurons in hippocampal slices from rat. Neuroscience Letters 2022;790:136898 · PMID 36195298
- Ito I, Tanabe S, Kohda A, Sugiyama H. Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. Journal of Physiology 1990;424:533-543 · PMID 1975272
- Secades JJ, Lorenzo JL. Citicoline: pharmacological and clinical review, 2006 update.. Methods Find Exp Clin Pharmacol 2006 · PMID 17171187
The other 5 routes to focus, memory & cognition
Pick the pathway that matches where you are actually stuck. An appetite drug does nothing for someone who already undereats.
You know the goal. Skool has the plan.
This pathway is one arm of The Focus, memory & cognition Blueprint. The members' version has where this arm sits in the sequence, what to stack it with, and the markers that tell you to keep going or stop.
Open The Focus, memory & cognition Blueprint in Skool →$10/mo, cancel anytime.
← Open this pathway in the interactive Vault
Frequently asked questions
Acetylcholine is the neurotransmitter of attention and memory formation. Most racetams increase acetylcholine turnover without supplying more, which is exactly why people get headaches on them and why a choline source is not optional in this pathway.
19 options are mapped to this pathway in the Vault, including Alpha-GPC, CDP-Choline, Piracetam, Aniracetam. They are grouped by the mechanism they act through rather than ranked by how much trial evidence exists — 7 carry clinical validation and 11 are mechanistic predictions.
Check these before buying a nootropic. B12 deficiency produces exactly the symptom picture racetams are sold for, serum B12 misses it, and MMA is the test that doesn't. The markers worth checking are Vitamin B12, Methylmalonic Acid (MMA), Folate, Serum, Homocysteine.
Unproven is not the same as ineffective. Of the 19 options on this pathway, 7 have clinical validation and 11 are graded theoretical — meaning the mechanism is sound but the specific human trial has not been run, which is true of a great deal of what works in this space. Nothing on this page is ordered by evidence tier, because sorting by trial count would bury the compounds you came looking for.
Where this goes next
Everything above is the free case for Cholinergic — attention, encoding & recall. The protocol — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.